Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H15ClO4 |
| Molecular Weight | 318.752 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(OC1=CC=C(C=C1)C(=O)C2=CC=C(Cl)C=C2)C(O)=O
InChI
InChIKey=MQOBSOSZFYZQOK-UHFFFAOYSA-N
InChI=1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)
| Molecular Formula | C17H15ClO4 |
| Molecular Weight | 318.752 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Photosensitization of thymine nucleobase by benzophenone derivatives as models for photoinduced DNA damage: Paterno-Büchi vs energy and electron transfer processes. | 2004 Jul |
|
| A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. | 2004 Sep |
|
| Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. | 2004 Sep |
|
| Fenofibric acid. | 2005 Feb |
|
| Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. | 2005 Jan |
|
| Troglitazone and 15-deoxy-delta(12,14)-prostaglandin J2 inhibit shear-induced coupling factor 6 release in endothelial cells. | 2005 Jul 1 |
|
| Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. | 2005 Oct 3 |
|
| Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. | 2005 Sep 15 |
|
| Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study. | 2005 Sep 15 |
|
| Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. | 2006 |
|
| The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. | 2006 May |
|
| Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. | 2006 Nov 24 |
|
| The transfer of a LC-UV method for the determination of fenofibrate and fenofibric acid in Lidoses: use of total error as decision criterion. | 2006 Sep 11 |
|
| Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. | 2007 |
|
| Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum. | 2007 Apr |
|
| Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. | 2007 Aug |
|
| Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. | 2007 Aug |
|
| Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LbetaT2 cells. | 2007 Jul |
|
| Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. | 2007 May |
|
| Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. | 2008 |
|
| Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells. | 2008 |
|
| Nanocrystal technology, drug delivery and clinical applications. | 2008 |
|
| Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. | 2008 |
|
| Cryptochrome and Period Proteins Are Regulated by the CLOCK/BMAL1 Gene: Crosstalk between the PPARs/RXRalpha-Regulated and CLOCK/BMAL1-Regulated Systems. | 2008 |
|
| Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. | 2008 Apr 28 |
|
| A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet. | 2008 May |
|
| An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection. | 2008 May 2 |
|
| Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid. | 2008 May-Jun |
|
| Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. | 2009 |
|
| MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation. | 2009 |
|
| Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression. | 2009 Apr |
|
| Fenofibrate-loaded PLGA microparticles: effects on ischemic stroke. | 2009 Apr 11 |
|
| Advances in the medical treatment of diabetic retinopathy. | 2009 Aug |
|
| Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier. | 2009 Aug |
|
| Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature. | 2009 Dec |
|
| Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. | 2009 Feb 15 |
|
| Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. | 2009 Jan |
|
| ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. | 2009 Jan |
|
| Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine. | 2009 Jun |
|
| Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. | 2009 Jun |
|
| Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein. | 2009 Jun |
|
| Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. | 2009 May |
|
| Fenofibric Acid (trilipix). | 2009 May 4 |
|
| In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. | 2009 Nov |
|
| Myopathy with statin-fibrate combination therapy: clinical considerations. | 2009 Sep |
|
| Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. | 2009 Sep |
|
| Probing the fibrate binding specificity of rat liver fatty acid binding protein. | 2009 Sep 10 |
|
| Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. | 2010 |
|
| Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain. | 2010 Apr |
|
| Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms. | 2010 Jan |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Oct 21 23:48:50 UTC 2019
by
admin
on
Mon Oct 21 23:48:50 UTC 2019
|
| Record UNII |
BGF9MN2HU1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000175596
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
||
|
NCI_THESAURUS |
C98150
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24852
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | RxNorm | ||
|
42017-89-0
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
64929
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
SUB34521
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
42017-89-0
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
Fenofibric acid
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
M5279
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
CHEMBL981
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
C83804
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
C006012
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY | |||
|
255-626-9
Created by
admin on Mon Oct 21 23:48:50 UTC 2019 , Edited by admin on Mon Oct 21 23:48:50 UTC 2019
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
